Market capitalisation
?
Share price multiplied by shares outstanding. It does not measure company cash.
Company analysis·JNJ
Preparing the analysis
We’re preparing the company’s analysis.
NYSE·JNJ
Johnson & Johnson
Share price$278.32Price as of: Nov 9, 2026
Johnson & Johnson (JNJ) is a company listed on NYSE, classified under Drug Manufacturers - General.
Johnson & Johnson is a healthcare holding company with operations in Innovative Medicine and MedTech.
Revenue · FY 2025
?
Sales generated during the period, before costs and expenses.
Net margin · FY 2025
?
Net income as a proportion of revenue.
“Our take” and other explanations are generated with artificial intelligence from the data, without human review of each text. They are descriptive, not recommendations. Learn more
Explore questions
P1 · What does it do and how does it make money?
Of every $100 it takes in,64 come from Innovative Medicine.
Innovative Medicine is its largest source of revenue (64.1%), followed by MedTech (35.9%). Here you will see what it sells, where, and how that mix is changing.
$94bnrevenue in FY 2025
2business lines with data
57%of sales, in UNITED STATES
Full fiscal year ended Dec 28, 2025
After that close
Q3 2026, ended Sep 27, 2026: total revenue +5.9% against the same quarter a year earlier.
This is the revenue of the whole company. The split by lines and regions on this page is still that of the full fiscal year.01How it makes money
The data does not separate products from services.
Not all revenue behaves the same way. A one-off sale depends on someone buying again; a service is billed again and again while the customer stays.
Its business lines · FY 2025
02Where revenue comes from
A single line brings in half or more.
Each rectangle is a business line and its size is the share of revenue it brings in. Select one to see the detail.
Area = share of total revenue for the year. It does not show profit: the company does not report what each line earns.
What is a segment's weight?
The part of everything the company takes in that comes from that line. If a line weighs 49%, then of every 100 in sales, 49 come from it.
How to read it
The more a line weighs, the more revenue depends on it. A high weight is neither good nor bad by itself: it shows where to look first.
03Where sales come from
It depends on one main market.
UNITED STATES is its largest market, with 57.1% of sales. Each square is a region and its area is what it sells there.
Regions from largest to smallest · FY 2025
04How the mix is changing
The mix barely changes.
Weight of each part in 2024 and in 2025. A line gains weight when it grows faster than the total.
FY 2024FY 2025
pp = percentage points: the difference between two percentages (from 25% to 27% is 2 pp).
05Read with care
What we can deduce from the data. And what we cannot.
We can deduceWe cannot conclude
01
The United States drove growth more than proportional to its weight (64.2% of the increase with 56.6% of revenue).
That growth is balanced by region: even if Europe grows slightly faster than average, the actual regional contribution still comes mostly from the US.
02
MedTech grows almost as fast as Innovative Medicine (+6.1%), but its smaller weight means the overall mix barely shifts.
That MedTech is closing the gap: even matching the rate, its impact on the total remains limited as long as its size is smaller.
Our take
Johnson & Johnson’s FY 2025 structure still depends on Innovative Medicine and the US market, with no shift from the previous year.
- 01Shown by the figures
Innovative Medicine remains dominant
Despite balanced revenue growth across lines, the share of Innovative Medicine remains constant in FY 2025 (64.1%). MedTech grows at the same rate but remains much smaller in volume.
- 02Shown by the figures
Growth comes from the US
Although Europe accelerates (+6.5%), most of the uplift comes from the US, contributing more increase than its weight. Other regions add comparatively little.
See the calculations behind it
- Innovative Medicine brought $3.4B of the $5.4B by which revenue grew in FY 2025 (64.0%), although it weighed 64.1%. Without that line, the rest grew 6.1%.
- Dependence on Innovative Medicine barely changes: 64.1% of revenue in FY 2024 and 64.1% in FY 2025.
- United States brings 57.1% of sales (56.6% in FY 2024). The fastest-growing region is Europe: +6.5% against +6.0% overall.
- Innovative Medicine accounts for 64.0% of the change in revenue in FY 2025 and weighed 64.1%.
- Innovative Medicine weighs more than all the other lines together: 64.1% of revenue in FY 2025.
- United States brought 64.2% of the growth in sales by region in FY 2025, weighing 56.6%.
With data to Nov 4, 2026. Analysis written by a language model from our calculations, which supply every figure. It is not investment advice.
Next step